# Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct07819604/  
OnCo record `nct07819604` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of serplulimab, cAPOX (capecitabine, oxaliplatin) and bevacizumab (glioblastoma use) in colorectal cancer, run by Xijing Hospital, not yet recruiting.

## Summary

Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer is a phase 2, interventional study registered as NCT07819604 by Xijing Hospital, with a registry enrolment figure of 85 participants, started 2026-09-01 and due to reach its primary completion in 2027-09-01. Interventions recorded: Serplulimab; CAPOX; Bevacizumab. Conditions listed: Locally Advanced Colorectal Cancer. Primary outcome: Pathological Complete Response (pCR) Rate. Colorectal eligibility wording from the registry: "* Histologically or pathologically confirmed locally advanced rectal adenocarcinoma, cT3/cT4N+M0 stage per AJCC/UICC 8th edition, with distance from anal verge ≤10 cm". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07819604
- Phase: 2
- Setting: A Single-Arm, Phase II, Multicenter Study of Serplulimab Combined With CAPOX Plus Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
- Sponsor: Xijing Hospital
- Enrolled: 85

## Sources

- ClinicalTrials.gov NCT07819604: https://clinicaltrials.gov/study/NCT07819604

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Serplulimab](https://onco.cc/drugs/serplulimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07819604.json